Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Abstract

BackgroundBladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation of the PI3K/AKT/mTOR pathway was observed in more than 40% of bladder tumors and suggested the use of mTOR as a target for the treatment of urothelial cancers.MethodsThis trial assessed the efficacy of temsirolimus in a homogenous cohort of patients with recurrent or metastatic bladder cancer following first-line chemotherapy. Efficacy was measured in terms of non-progression at two months according to the RECIST v1.1 criteria. Based on a two-stage optimal Simon’s design, 15 non-progressions out of 51 evaluable patients were required to claim efficacy. Patients were treated at a weekly dose of 25 mg IV until progression, unacceptable toxicities or withdrawal.ResultsAmong the 54 patients enrolled in the study between November 2009 and July 2014, 45 were assessable for the primary efficacy endpoint. A total of 22 (48.9%) non-progressions were observed at 2 months with 3 partial responses and 19 stable diseases. Remarkably, 4 patients were treated for more than 30 weeks. Fifty patients experienced at least a related grade1/2 (94%) and twenty-eight patients (52.8%) a related grade 3/4 adverse event. Eleven patients had to stop treatment for toxicity. This led to recruitment being halted by an independent data monitoring committee with regard to the risk-benefit balance and the fact that the primary objective was already met.ConclusionsWhile the positivity of this trial indicates a potential benefit of temsirolimus for a subset of bladder cancer patients who are refractory to first line platinum-based chemotherapy, the risk of adverse events associated with the use of this mTOR inhibitor would need to be considered when such an option is envisaged in this frail population of patients. It also remains to identify patients who will benefit the most from this targeted therapy.Trial registrationClinicalTrials.gov Identifier: NCT01827943 (trial registration date: October 29, 2012); Retrospectively registered.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4059-5) contains supplementary material, which is available to authorized users.

The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies

“…At the present time, novel and tailor-made inhibitors of the cellular proteasome, AKT or MMPs are under evaluation [ 139 , 140 , 143 , 221 , 222 , 223 ], since the first generation of these drugs has given unsatisfactory results [ 123 , 124 , 135 , 136 , 137 , 138 , 224 , 225 ].…”

Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer

“…Recent studies also reported that multiple lncRNAs competitively bind miRNAs to regulate FASN expression in nasopharyngeal and endometrial cancer ( 47 , 48 ). For drugs targeting FASN, a phase II clinical trial revealed that temsirolimus show potential benefit in bladder cancer patients who are refractory to first line platinum-based chemotherapy ( 49 ). Our drug screening also revealed several drugs that target both SREBF1 and FASN, which may have better effects in BC patients.…”

Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review

“…However, 50 of 53 patients experienced grade 1 or 2 treatment related toxicity, and 28 patients had a grade 3 or 4 adverse event, so this high risk of adverse events must be weighed carefully against its therapeutic impact. The most common grade 3-4 AEs were hematologic toxicity [10(18.9%)], asthenia/fatigue [10(18.9%)], and gastrointestinal toxicity [6(11.3%)] ( 85 ).…”